JP2010523718A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010523718A5 JP2010523718A5 JP2010503260A JP2010503260A JP2010523718A5 JP 2010523718 A5 JP2010523718 A5 JP 2010523718A5 JP 2010503260 A JP2010503260 A JP 2010503260A JP 2010503260 A JP2010503260 A JP 2010503260A JP 2010523718 A5 JP2010523718 A5 JP 2010523718A5
- Authority
- JP
- Japan
- Prior art keywords
- addictive
- agonist
- additional therapeutic
- substance
- pparγ
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000126 substance Substances 0.000 claims 32
- 238000000034 method Methods 0.000 claims 22
- 108010016731 PPAR gamma Proteins 0.000 claims 18
- 230000001225 therapeutic effect Effects 0.000 claims 18
- 206010012335 Dependence Diseases 0.000 claims 15
- 239000002552 dosage form Substances 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 12
- 229940124597 therapeutic agent Drugs 0.000 claims 12
- -1 siglitazone Chemical compound 0.000 claims 11
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims 10
- 239000000556 agonist Substances 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 10
- 102000000536 PPAR gamma Human genes 0.000 claims 9
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims 9
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 8
- 230000002265 prevention Effects 0.000 claims 7
- 230000001575 pathological effect Effects 0.000 claims 5
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 4
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical group O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 4
- 229940123464 Thiazolidinedione Drugs 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- 239000000935 antidepressant agent Substances 0.000 claims 4
- 229940005513 antidepressants Drugs 0.000 claims 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 4
- 229960002715 nicotine Drugs 0.000 claims 4
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 4
- 239000003402 opiate agonist Substances 0.000 claims 4
- 239000003401 opiate antagonist Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229960005095 pioglitazone Drugs 0.000 claims 4
- 239000002464 receptor antagonist Substances 0.000 claims 4
- 229940044551 receptor antagonist Drugs 0.000 claims 4
- 230000001430 anti-depressive effect Effects 0.000 claims 3
- 229960003086 naltrexone Drugs 0.000 claims 3
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 3
- 239000003368 psychostimulant agent Substances 0.000 claims 3
- 229960004739 sufentanil Drugs 0.000 claims 3
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 claims 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 2
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims 2
- 244000025254 Cannabis sativa Species 0.000 claims 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims 2
- 101000957724 Catostomus commersonii Corticoliberin-1 Proteins 0.000 claims 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 2
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 2
- DEXMFYZAHXMZNM-UHFFFAOYSA-N Narceine Chemical compound OC(=O)C1=C(OC)C(OC)=CC=C1C(=O)CC1=C(CCN(C)C)C=C(OCO2)C2=C1OC DEXMFYZAHXMZNM-UHFFFAOYSA-N 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims 2
- 125000003158 alcohol group Chemical group 0.000 claims 2
- 239000001961 anticonvulsive agent Substances 0.000 claims 2
- 229960003965 antiepileptics Drugs 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 2
- 229960004193 dextropropoxyphene Drugs 0.000 claims 2
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims 2
- 229960002428 fentanyl Drugs 0.000 claims 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 2
- 229960001797 methadone Drugs 0.000 claims 2
- 230000002969 morbid Effects 0.000 claims 2
- 229960005181 morphine Drugs 0.000 claims 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 claims 2
- 239000004031 partial agonist Substances 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 claims 1
- UVITTYOJFDLOGI-UHFFFAOYSA-N (1,2,5-trimethyl-4-phenylpiperidin-4-yl) propanoate Chemical compound C=1C=CC=CC=1C1(OC(=O)CC)CC(C)N(C)CC1C UVITTYOJFDLOGI-UHFFFAOYSA-N 0.000 claims 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims 1
- XEXRNSZXUAPKBJ-HJOKCUNISA-N (4r,4ar,7ar,12bs)-9-hydroxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;(4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC XEXRNSZXUAPKBJ-HJOKCUNISA-N 0.000 claims 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims 1
- DVWTWOHVDUVPJV-JTQLQIEISA-N 2-n-[(1s)-1-(5-fluoropyrimidin-2-yl)ethyl]-7-methyl-4-n-(1-methylimidazol-4-yl)thieno[3,2-d]pyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1N=CC(F)=CN=1)C(N=C1C(C)=CSC1=1)=NC=1NC1=CN(C)C=N1 DVWTWOHVDUVPJV-JTQLQIEISA-N 0.000 claims 1
- IYNWSQDZXMGGGI-NUEKZKHPSA-N 3-hydroxymorphinan Chemical compound C1CCC[C@H]2[C@H]3CC4=CC=C(O)C=C4[C@]21CCN3 IYNWSQDZXMGGGI-NUEKZKHPSA-N 0.000 claims 1
- MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 claims 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 108091005471 CRHR1 Proteins 0.000 claims 1
- IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 claims 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 claims 1
- OGDVEMNWJVYAJL-UHFFFAOYSA-N Ethylmorphine Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OCC OGDVEMNWJVYAJL-UHFFFAOYSA-N 0.000 claims 1
- 208000001836 Firesetting Behavior Diseases 0.000 claims 1
- 208000001613 Gambling Diseases 0.000 claims 1
- 206010020710 Hyperphagia Diseases 0.000 claims 1
- ALFGKMXHOUSVAD-UHFFFAOYSA-N Ketobemidone Chemical compound C=1C=CC(O)=CC=1C1(C(=O)CC)CCN(C)CC1 ALFGKMXHOUSVAD-UHFFFAOYSA-N 0.000 claims 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 claims 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 claims 1
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 claims 1
- ONBWJWYUHXVEJS-ZTYRTETDSA-N Normorphine Chemical compound C([C@@H](NCC1)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 ONBWJWYUHXVEJS-ZTYRTETDSA-N 0.000 claims 1
- FRPRNNRJTCONEC-UHFFFAOYSA-N Ohmefentanyl Chemical group C=1C=CC=CC=1N(C(=O)CC)C(C(C1)C)CCN1CC(O)C1=CC=CC=C1 FRPRNNRJTCONEC-UHFFFAOYSA-N 0.000 claims 1
- 229940127450 Opioid Agonists Drugs 0.000 claims 1
- 239000008896 Opium Substances 0.000 claims 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims 1
- ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 claims 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 229960001391 alfentanil Drugs 0.000 claims 1
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 claims 1
- 229940025084 amphetamine Drugs 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- IXPROWGEHNVJOY-UHFFFAOYSA-N antalarmin Chemical group CC1=C(C)C=2C(N(CC)CCCC)=NC(C)=NC=2N1C1=C(C)C=C(C)C=C1C IXPROWGEHNVJOY-UHFFFAOYSA-N 0.000 claims 1
- 230000003474 anti-emetic effect Effects 0.000 claims 1
- 230000003556 anti-epileptic effect Effects 0.000 claims 1
- 229940125683 antiemetic agent Drugs 0.000 claims 1
- 239000002111 antiemetic agent Substances 0.000 claims 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims 1
- 229960004046 apomorphine Drugs 0.000 claims 1
- 229940125717 barbiturate Drugs 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 150000001557 benzodiazepines Chemical class 0.000 claims 1
- RDJGWRFTDZZXSM-RNWLQCGYSA-N benzylmorphine Chemical compound O([C@@H]1[C@]23CCN([C@H](C4)[C@@H]3C=C[C@@H]1O)C)C1=C2C4=CC=C1OCC1=CC=CC=C1 RDJGWRFTDZZXSM-RNWLQCGYSA-N 0.000 claims 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 1
- 229960001736 buprenorphine Drugs 0.000 claims 1
- 229960001058 bupropion Drugs 0.000 claims 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 1
- YDSDEBIZUNNPOB-UHFFFAOYSA-N carfentanil Chemical compound C1CN(CCC=2C=CC=CC=2)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 YDSDEBIZUNNPOB-UHFFFAOYSA-N 0.000 claims 1
- 229950004689 carfentanil Drugs 0.000 claims 1
- GPZLDQAEBHTMPG-UHFFFAOYSA-N clonitazene Chemical compound N=1C2=CC([N+]([O-])=O)=CC=C2N(CCN(CC)CC)C=1CC1=CC=C(Cl)C=C1 GPZLDQAEBHTMPG-UHFFFAOYSA-N 0.000 claims 1
- 229950001604 clonitazene Drugs 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 229960004126 codeine Drugs 0.000 claims 1
- 231100000867 compulsive behavior Toxicity 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- INUNXTSAACVKJS-OAQYLSRUSA-N dextromoramide Chemical compound C([C@@H](C)C(C(=O)N1CCCC1)(C=1C=CC=CC=1)C=1C=CC=CC=1)N1CCOCC1 INUNXTSAACVKJS-OAQYLSRUSA-N 0.000 claims 1
- 229960003701 dextromoramide Drugs 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- 229950001059 diampromide Drugs 0.000 claims 1
- RXTHKWVSXOIHJS-UHFFFAOYSA-N diampromide Chemical compound C=1C=CC=CC=1N(C(=O)CC)CC(C)N(C)CCC1=CC=CC=C1 RXTHKWVSXOIHJS-UHFFFAOYSA-N 0.000 claims 1
- 229960000920 dihydrocodeine Drugs 0.000 claims 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims 1
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 claims 1
- RHUWRJWFHUKVED-UHFFFAOYSA-N dimenoxadol Chemical compound C=1C=CC=CC=1C(C(=O)OCCN(C)C)(OCC)C1=CC=CC=C1 RHUWRJWFHUKVED-UHFFFAOYSA-N 0.000 claims 1
- 229950011187 dimenoxadol Drugs 0.000 claims 1
- QIRAYNIFEOXSPW-UHFFFAOYSA-N dimepheptanol Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(O)CC)C1=CC=CC=C1 QIRAYNIFEOXSPW-UHFFFAOYSA-N 0.000 claims 1
- SVDHSZFEQYXRDC-UHFFFAOYSA-N dipipanone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CC(C)N1CCCCC1 SVDHSZFEQYXRDC-UHFFFAOYSA-N 0.000 claims 1
- 229960002500 dipipanone Drugs 0.000 claims 1
- 229950002375 englitazone Drugs 0.000 claims 1
- WGJHHMKQBWSQIY-UHFFFAOYSA-N ethoheptazine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCCN(C)CC1 WGJHHMKQBWSQIY-UHFFFAOYSA-N 0.000 claims 1
- 229960000569 ethoheptazine Drugs 0.000 claims 1
- 229960004578 ethylmorphine Drugs 0.000 claims 1
- 229950004155 etorphine Drugs 0.000 claims 1
- CAHCBJPUTCKATP-FAWZKKEFSA-N etorphine Chemical compound O([C@H]1[C@@]2(OC)C=C[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O CAHCBJPUTCKATP-FAWZKKEFSA-N 0.000 claims 1
- 229960002464 fluoxetine Drugs 0.000 claims 1
- 229960002870 gabapentin Drugs 0.000 claims 1
- 230000002650 habitual effect Effects 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 1
- 208000015046 intermittent explosive disease Diseases 0.000 claims 1
- IFKPLJWIEQBPGG-UHFFFAOYSA-N isomethadone Chemical compound C=1C=CC=CC=1C(C(C)CN(C)C)(C(=O)CC)C1=CC=CC=C1 IFKPLJWIEQBPGG-UHFFFAOYSA-N 0.000 claims 1
- 229950009272 isomethadone Drugs 0.000 claims 1
- 229960003029 ketobemidone Drugs 0.000 claims 1
- 206010023461 kleptomania Diseases 0.000 claims 1
- 229960004002 levetiracetam Drugs 0.000 claims 1
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 claims 1
- RCYBMSQOSGJZLO-BGWNEDDSSA-N levophenacylmorphan Chemical compound C([C@]12CCCC[C@H]1[C@H]1CC3=CC=C(C=C32)O)CN1CC(=O)C1=CC=CC=C1 RCYBMSQOSGJZLO-BGWNEDDSSA-N 0.000 claims 1
- 229960003406 levorphanol Drugs 0.000 claims 1
- IMYHGORQCPYVBZ-NLFFAJNJSA-N lofentanil Chemical compound CCC(=O)N([C@@]1([C@@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 IMYHGORQCPYVBZ-NLFFAJNJSA-N 0.000 claims 1
- 229950010274 lofentanil Drugs 0.000 claims 1
- FQXXSQDCDRQNQE-UHFFFAOYSA-N markiertes Thebain Natural products COC1=CC=C2C(N(CC3)C)CC4=CC=C(OC)C5=C4C23C1O5 FQXXSQDCDRQNQE-UHFFFAOYSA-N 0.000 claims 1
- YGSVZRIZCHZUHB-COLVAYQJSA-N metazocine Chemical compound C1C2=CC=C(O)C=C2[C@]2(C)CCN(C)[C@@]1([H])[C@@H]2C YGSVZRIZCHZUHB-COLVAYQJSA-N 0.000 claims 1
- 229950009131 metazocine Drugs 0.000 claims 1
- 229960001785 mirtazapine Drugs 0.000 claims 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 claims 1
- 229960005297 nalmefene Drugs 0.000 claims 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims 1
- 229960004127 naloxone Drugs 0.000 claims 1
- 239000003887 narcotic antagonist Substances 0.000 claims 1
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 claims 1
- 229960004300 nicomorphine Drugs 0.000 claims 1
- HNDXBGYRMHRUFN-CIVUWBIHSA-N nicomorphine Chemical compound O([C@H]1C=C[C@H]2[C@H]3CC=4C5=C(C(=CC=4)OC(=O)C=4C=NC=CC=4)O[C@@H]1[C@]52CCN3C)C(=O)C1=CC=CN=C1 HNDXBGYRMHRUFN-CIVUWBIHSA-N 0.000 claims 1
- 229950011519 norlevorphanol Drugs 0.000 claims 1
- 229960004013 normethadone Drugs 0.000 claims 1
- WCJFBSYALHQBSK-UHFFFAOYSA-N normethadone Chemical compound C=1C=CC=CC=1C(CCN(C)C)(C(=O)CC)C1=CC=CC=C1 WCJFBSYALHQBSK-UHFFFAOYSA-N 0.000 claims 1
- 229950006134 normorphine Drugs 0.000 claims 1
- 229950007418 norpipanone Drugs 0.000 claims 1
- WCDSHELZWCOTMI-UHFFFAOYSA-N norpipanone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CCN1CCCCC1 WCDSHELZWCOTMI-UHFFFAOYSA-N 0.000 claims 1
- 229960004708 noscapine Drugs 0.000 claims 1
- 229960005343 ondansetron Drugs 0.000 claims 1
- 229960001027 opium Drugs 0.000 claims 1
- 235000020830 overeating Nutrition 0.000 claims 1
- 229960002085 oxycodone Drugs 0.000 claims 1
- 229960005118 oxymorphone Drugs 0.000 claims 1
- 229960001789 papaverine Drugs 0.000 claims 1
- 239000003614 peroxisome proliferator Substances 0.000 claims 1
- 229960000482 pethidine Drugs 0.000 claims 1
- LOXCOAXRHYDLOW-UHFFFAOYSA-N phenadoxone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CC(C)N1CCOCC1 LOXCOAXRHYDLOW-UHFFFAOYSA-N 0.000 claims 1
- 229950004540 phenadoxone Drugs 0.000 claims 1
- CFBQYWXPZVQQTN-QPTUXGOLSA-N phenomorphan Chemical compound C([C@]12CCCC[C@H]1[C@H]1CC3=CC=C(C=C32)O)CN1CCC1=CC=CC=C1 CFBQYWXPZVQQTN-QPTUXGOLSA-N 0.000 claims 1
- 229950011496 phenomorphan Drugs 0.000 claims 1
- IPOPQVVNCFQFRK-UHFFFAOYSA-N phenoperidine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(O)C1=CC=CC=C1 IPOPQVVNCFQFRK-UHFFFAOYSA-N 0.000 claims 1
- 229960004315 phenoperidine Drugs 0.000 claims 1
- 229950004345 properidine Drugs 0.000 claims 1
- XJKQCILVUHXVIQ-UHFFFAOYSA-N properidine Chemical compound C=1C=CC=CC=1C1(C(=O)OC(C)C)CCN(C)CC1 XJKQCILVUHXVIQ-UHFFFAOYSA-N 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 229960003394 remifentanil Drugs 0.000 claims 1
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 claims 1
- 229960003015 rimonabant Drugs 0.000 claims 1
- 229960004586 rosiglitazone Drugs 0.000 claims 1
- 229930003945 thebaine Natural products 0.000 claims 1
- FQXXSQDCDRQNQE-VMDGZTHMSA-N thebaine Chemical compound C([C@@H](N(CC1)C)C2=CC=C3OC)C4=CC=C(OC)C5=C4[C@@]21[C@H]3O5 FQXXSQDCDRQNQE-VMDGZTHMSA-N 0.000 claims 1
- 229960004394 topiramate Drugs 0.000 claims 1
- 229960004380 tramadol Drugs 0.000 claims 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims 1
- 229960001641 troglitazone Drugs 0.000 claims 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91120107P | 2007-04-11 | 2007-04-11 | |
| US60/911,201 | 2007-04-11 | ||
| PCT/US2008/060146 WO2008128126A1 (en) | 2007-04-11 | 2008-04-11 | Compositions and methods for prophylaxis and treatment of addictions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014056079A Division JP6010572B2 (ja) | 2007-04-11 | 2014-03-19 | 嗜癖の予防および治療のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010523718A JP2010523718A (ja) | 2010-07-15 |
| JP2010523718A5 true JP2010523718A5 (enExample) | 2012-05-24 |
| JP5548120B2 JP5548120B2 (ja) | 2014-07-16 |
Family
ID=39864359
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010503260A Active JP5548120B2 (ja) | 2007-04-11 | 2008-04-11 | 嗜癖の予防および治療のための組成物および方法 |
| JP2014056079A Active JP6010572B2 (ja) | 2007-04-11 | 2014-03-19 | 嗜癖の予防および治療のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014056079A Active JP6010572B2 (ja) | 2007-04-11 | 2014-03-19 | 嗜癖の予防および治療のための組成物および方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8426439B2 (enExample) |
| EP (4) | EP2141989B1 (enExample) |
| JP (2) | JP5548120B2 (enExample) |
| KR (1) | KR101622403B1 (enExample) |
| CN (3) | CN105250285B (enExample) |
| AU (1) | AU2008240158B2 (enExample) |
| BR (1) | BRPI0810525B8 (enExample) |
| CA (1) | CA2684059C (enExample) |
| ES (4) | ES2438768T3 (enExample) |
| MX (2) | MX356965B (enExample) |
| NZ (1) | NZ580963A (enExample) |
| RU (1) | RU2492858C2 (enExample) |
| WO (1) | WO2008128126A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090066289A (ko) | 2006-09-08 | 2009-06-23 | 로드아일랜드하스피틀 | 알코올 유발성 뇌 질환의 치료, 예방 및 역행 |
| US20160331729A9 (en) | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| US8426439B2 (en) * | 2007-04-11 | 2013-04-23 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| AU2013202267B2 (en) * | 2007-04-11 | 2015-03-19 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| MX2010012989A (es) * | 2008-05-30 | 2011-04-27 | Mylan Inc | Sistema de suministro de farmaco transdermico estabilizado. |
| CN102307895A (zh) | 2008-12-04 | 2012-01-04 | 里兰斯坦福初级大学理事会 | 用于治疗或预防麻醉药停药症状的方法和组合物 |
| JP6163289B2 (ja) * | 2009-03-11 | 2017-07-12 | オメロス コーポレーション | 嗜癖の予防および治療のための組成物および方法 |
| EP2846805B1 (en) * | 2012-05-07 | 2018-11-21 | Omeros Corporation | Treatment of addiction and impulse-control disorders using pde7 inhibitors |
| LT2846805T (lt) * | 2012-05-07 | 2019-02-25 | Omeros Corporation | Priklausomybių ir impulsų kontrolės sutrikimų gydymas, panaudojant pde7 inhibitorius |
| EP2866817A4 (en) * | 2012-07-06 | 2016-04-20 | Omeros Corp | ANDROGRAPHIS PANICULATE COMPOSITIONS AND METHOD FOR TREATING ADDICTIVE DISEASES |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| US20150051191A1 (en) * | 2013-08-15 | 2015-02-19 | Medicinova, Inc. | Treatment of alcoholism using ibudilast |
| WO2015153263A1 (en) * | 2014-04-02 | 2015-10-08 | Yale University | Compositions and methods to treat addiction |
| WO2016065177A1 (en) * | 2014-10-22 | 2016-04-28 | The Trustees Of The University Of Pennsylvania | Method of treating depression and other stress related disorders |
| KR101960262B1 (ko) * | 2016-04-08 | 2019-03-21 | 공주대학교 산학협력단 | 전자 담배 조성물 내 담배 특이 니트로스아민류 및 카르보닐 화합물을 제거 및 생성의 억제, 전자 담배 조성물 흡연 시 발생하는 카르보닐 화합물 제거, 및 니코틴액의 갈변을 막기 위한 전자 담배 니코틴액용 첨가제 및 이를 포함하는 전자 담배 조성물 |
| WO2018204689A1 (en) * | 2017-05-04 | 2018-11-08 | The Board Of Regents Of The University Of Texas System | Methods of treating synthetic cannabinoid toxicity or overdose with rimonabant |
| KR102208012B1 (ko) * | 2017-12-20 | 2021-01-27 | 가톨릭대학교 산학협력단 | 코카인 중독 특이적 바이오 마커 |
| US20220142985A1 (en) * | 2018-08-10 | 2022-05-12 | Servicio Andaluz De Salud | Agents for treatment of alcohol use disorder |
| US10966938B2 (en) | 2019-01-04 | 2021-04-06 | Jonand4, Llc | Composition and method for preventing or treating hangover symptoms |
| CN112569237B (zh) * | 2019-09-30 | 2022-12-02 | 武汉大学 | 伊马替尼及其衍生物与尼古丁或其类似物联用或复方在防治尼古丁成瘾与复吸中的应用 |
| CN114796446B (zh) * | 2021-01-22 | 2024-08-30 | 宁夏杞肽科技有限公司 | 孤啡肽治疗氯胺酮成瘾的用途 |
| EP4486448A1 (en) | 2022-03-04 | 2025-01-08 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3788207A (en) | 1972-05-26 | 1974-01-29 | Doherty Silentaire | Top discharge roof ventilator |
| JPS6051189A (ja) | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | チアゾリジン誘導体およびその製造法 |
| US4582839A (en) | 1984-03-21 | 1986-04-15 | Takeda Chemical Industries, Ltd. | 2,4-thiazolidinediones |
| CN1003445B (zh) | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物，其制备方法和用途 |
| AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
| JPH06779B2 (ja) * | 1985-06-10 | 1994-01-05 | 武田薬品工業株式会社 | チアゾリジオン誘導体およびそれを含んでなる医薬組成物 |
| US4812570A (en) * | 1986-07-24 | 1989-03-14 | Takeda Chemical Industries, Ltd. | Method for producing thiazolidinedione derivatives |
| TW438587B (en) * | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| GB9604242D0 (en) | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| FR2749583B1 (fr) * | 1996-06-07 | 1998-08-21 | Lipha | Nouveaux derives de thiazolidine -2,4- dione substitues, leurs procedes d'obtention et les compositions pharmaceutiques en renfermant |
| US6011049A (en) * | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
| SE9702305D0 (sv) | 1997-06-17 | 1997-06-17 | Astra Ab | New thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives |
| US7098025B1 (en) | 1997-07-25 | 2006-08-29 | Ligand Pharmaceuticals Incorporated | Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor |
| AU749505B2 (en) * | 1997-10-27 | 2002-06-27 | Dr. Reddy's Laboratories Limited | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them |
| US20040028735A1 (en) * | 1997-11-14 | 2004-02-12 | Unchalee Kositprapa | Pharmaceutical formulation |
| US6541669B1 (en) | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
| WO2000000194A1 (en) * | 1998-06-27 | 2000-01-06 | Photogenesis, Inc. | Ophthalmic uses of ppargamma agonists and ppargamma antagonists |
| DK1180686T3 (da) | 1999-05-27 | 2010-01-04 | Cmic Co Ltd | Lægemidler til nyresygdomme og fremgangsmåde til screening deraf |
| US6582738B2 (en) * | 1999-09-13 | 2003-06-24 | Deseret Laboratories, Inc. | Process for preparing chewing gum containing a nutritional supplement |
| KR20020047198A (ko) * | 1999-09-30 | 2002-06-21 | 해피 페너 ; 해리 에이치. 페너 2세 | 특정 알킬렌 디아민-치환된피라졸로[1,5-ａ]-1,5-피리미딘 및피라졸로[1,5-ａ]-1,3,5-트리아진 |
| OA12050A (en) * | 1999-09-30 | 2006-05-02 | Neurogen Corp | Certain alkylene diamine-substituted heterocycles. |
| US20020006942A1 (en) | 2000-02-24 | 2002-01-17 | Davis Roger A. | Methods of treating liver disorders and disorders associated with liver function |
| IL151517A0 (en) | 2000-03-09 | 2003-04-10 | Aventis Pharma Gmbh | Therapeutic uses of ppar mediators |
| US6620830B2 (en) * | 2000-04-21 | 2003-09-16 | Pfizer, Inc. | Thyroid receptor ligands |
| US7510728B2 (en) * | 2000-10-06 | 2009-03-31 | Takeda Pharmaceutical Company Limited | Solid preparations |
| GB0030845D0 (en) | 2000-12-18 | 2001-01-31 | Smithkline Beecham Plc | Novel treatment |
| KR100965201B1 (ko) * | 2001-06-12 | 2010-06-24 | 웰스테트 테라퓨틱스 코포레이션 | 대사 질환의 치료용 화합물 |
| US7067530B2 (en) | 2001-07-30 | 2006-06-27 | Novo Nordisk A/S | Compounds, their preparation and use |
| EP1452521A4 (en) * | 2001-08-17 | 2007-03-14 | Eisai R&D Man Co Ltd | CYCLIC COMPOUND AND AGONIST OF PPAR RECEPTOR |
| AU2002337749A1 (en) | 2001-09-28 | 2003-04-07 | Teva Pharmaceutical Industries Ltd. | Pioglitazone hydrochloride |
| KR20050035142A (ko) * | 2001-10-11 | 2005-04-15 | 카네카 코포레이션 | 페록시좀 증식제 응답성 수용체 리간드제 및 그 제조 방법 |
| IL161431A0 (en) * | 2001-10-16 | 2004-09-27 | Reddys Lab Ltd Dr | beta-PHENYL-alpha-OXYSUBSTITUTED PROPIONIC ACID DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| AR037429A1 (es) | 2001-11-26 | 2004-11-10 | Schering Corp | Derivados de piperidina antagonistas de la mch, composiciones farmaceuticas, un proceso para su elaboracion y el uso de dichos derivados, solos o en combinacion, para la fabricacion de un medicamento para tratamiento de la obesidad y de trastornos del snc |
| US20050096331A1 (en) * | 2001-12-21 | 2005-05-05 | Das Saibal K. | Novel compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them |
| SE0201937D0 (sv) | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | Therapeutic agents |
| US7141561B2 (en) * | 2002-07-25 | 2006-11-28 | Sanofi-Aventis Deutschland Gmbh | Substituted diaryl heterocycles, process for their preparation and their use as medicaments |
| CA2493913A1 (en) | 2002-07-30 | 2004-02-05 | Merck & Co., Inc. | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
| US7985422B2 (en) * | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| JP2006500378A (ja) | 2002-08-21 | 2006-01-05 | メルク エンド カムパニー インコーポレーテッド | 二元ＰＰＡＲα／γアゴニストとアンギオテンシンＩＩのＩ型受容体アンタゴニストを使用する併用療法 |
| WO2004066963A2 (en) * | 2003-01-17 | 2004-08-12 | Merck & Co., Inc. | N-cyclohexylaminocarbonyl benzenesulfonamide derivatives |
| CA2513660C (en) * | 2003-01-23 | 2012-05-08 | Esperion Therapeutics, Inc. | Hydroxyl compounds and compositions for cholesterol management and related uses |
| US20040204472A1 (en) * | 2003-03-04 | 2004-10-14 | Pharmacia Corporation | Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents |
| WO2004092417A2 (en) | 2003-04-07 | 2004-10-28 | Emory University | Molecular correlates of cocaine addiction and methods for their use |
| WO2004093910A1 (ja) | 2003-04-22 | 2004-11-04 | Astellas Pharma Inc. | ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤 |
| US20050004179A1 (en) * | 2003-05-22 | 2005-01-06 | Pedersen Ward A. | Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease |
| WO2005000217A2 (en) | 2003-06-06 | 2005-01-06 | Merck & Co., Inc. | Combination therapy for the treatment of dyslipidemia |
| EP1635832A2 (en) * | 2003-06-06 | 2006-03-22 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes |
| US20060160834A1 (en) | 2003-06-06 | 2006-07-20 | Fong Tung M | Combination therapy for the treatment of hypertension |
| US7276608B2 (en) * | 2003-07-11 | 2007-10-02 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
| US7326706B2 (en) * | 2003-08-15 | 2008-02-05 | Bristol-Myers Squibb Company | Pyrazine modulators of cannabinoid receptors |
| CN1849120A (zh) * | 2003-09-10 | 2006-10-18 | 默克公司 | 作为雄激素受体调节剂的17－杂环－4－氮杂甾类衍生物 |
| EP1670460B1 (en) * | 2003-10-10 | 2014-11-26 | Bristol-Myers Squibb Company | Pyrazole derivatives as cannabinoid receptor modulators |
| CN1871005B (zh) * | 2003-10-31 | 2010-10-27 | 默沙东公司 | 雄激素受体调节剂21-杂环-4-氮杂甾体衍生物 |
| CN1897939A (zh) | 2003-10-31 | 2007-01-17 | 詹森药业有限公司 | 适用作过氧化物酶体增生物激活受体（ppar）双重激动剂的苯氧基乙酸衍生物 |
| EP1689757B1 (en) * | 2003-11-12 | 2014-08-27 | Phenomix Corporation | Heterocyclic boronic acid compounds |
| HRP20070241T3 (hr) | 2003-12-19 | 2007-07-31 | Bristol-Myers Squibb Company | Azabiciklički heterocikli kao modulatori kanabinoid receptora |
| ES2284081T3 (es) * | 2003-12-19 | 2007-11-01 | Bristol-Myers Squibb Company | Heterociclos azabiciclicos como modulares de receptores canabinoides. |
| TW200530246A (en) | 2003-12-19 | 2005-09-16 | Bristol Myers Squibb Co | Azabicyclic heterocycles as cannabinoid receptor modulators |
| BRPI0507786A (pt) | 2004-02-20 | 2007-07-17 | Astrazeneca Ab | composto e sais farmaceuticamente aceitáveis do mesmo, formulação farmacêutica, uso de um composto, método de tratar uma doença, e, processo para a preparação de compostos |
| KR20060133084A (ko) | 2004-04-03 | 2006-12-22 | 아스트라제네카 아베 | 치료제 |
| WO2005101979A2 (en) * | 2004-04-22 | 2005-11-03 | Mor Research Applications Ltd. | Method of food intake management |
| DE602005019555D1 (de) * | 2004-05-06 | 2010-04-08 | Galderma Res & Dev | Biaromatische verbindungen, die rezeptoren des typs ppar(gamma) aktivieren, verfahren zu deren herstellung und deren verwendung in kosmetischen oder pharmazeutischen zusammensetzungen |
| CA2573848A1 (en) * | 2004-07-12 | 2006-02-16 | Phenomix Corporation | Constrained cyano compounds |
| DE102004038270A1 (de) * | 2004-08-06 | 2006-03-16 | Sanofi-Aventis Deutschland Gmbh | Substituierte, bizyklische 8-Amino-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| CA2575995A1 (en) * | 2004-08-13 | 2006-02-16 | Omeros Corporation | Treatment for methamphetamine addiction and reduction of methamphetamine use using serotonin antagonists |
| JP2006065511A (ja) * | 2004-08-25 | 2006-03-09 | Fujitsu Ltd | 閲覧履歴提示システム |
| WO2006028970A1 (en) * | 2004-09-02 | 2006-03-16 | Cengent Therapeutics, Inc. | Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases |
| PE20060594A1 (es) | 2004-09-09 | 2006-08-18 | Novartis Ag | Composicion farmaceutica que contiene un agonista de ppar |
| WO2006042245A1 (en) | 2004-10-11 | 2006-04-20 | Dr. Reddy's Laboratories Ltd. | Novel isoxazole compounds having ppar agonist activity |
| US20060252670A1 (en) * | 2004-10-14 | 2006-11-09 | Intercept Pharmaceuticals Inc. | Method of reducing drug-induced adverse side effects in a patient |
| GB0425758D0 (en) * | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| GB0426301D0 (en) * | 2004-11-30 | 2004-12-29 | Vectura Ltd | Pharmaceutical formulations |
| CN101098690A (zh) * | 2004-12-06 | 2008-01-02 | 瑞莱恩特医药品有限公司 | 用于血脂治疗的ω-3脂肪酸和脂血异常剂 |
| US7411071B2 (en) * | 2005-01-13 | 2008-08-12 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US7737155B2 (en) * | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| US7750015B2 (en) * | 2005-05-17 | 2010-07-06 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| US20060270722A1 (en) | 2005-05-31 | 2006-11-30 | Thornberry Nancy A | Combination of a dipeptidyl peptidase-IV inhibitor and a dual PPAR agonist for the treatment of diabetes and obesity |
| US7795436B2 (en) * | 2005-08-24 | 2010-09-14 | Bristol-Myers Squibb Company | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists |
| JP2009506069A (ja) * | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| EP1976848A2 (en) * | 2005-12-21 | 2008-10-08 | Schering Corporation | Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists |
| WO2007079239A2 (en) * | 2005-12-30 | 2007-07-12 | Acadia Pharmaceuticals Inc. | Bicyclic nitrogen compounds as modulators of ghrelin receptor and uses thereof |
| US7429575B2 (en) * | 2006-01-10 | 2008-09-30 | Yu Ruey J | N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use |
| US20070197606A1 (en) * | 2006-02-22 | 2007-08-23 | Burczynski Frank J | Use of ppar agonists as anti-oxidants |
| US20070232573A1 (en) * | 2006-03-06 | 2007-10-04 | Avestha Gengraine Technologies Pvt. Ltd. | Ethanoic acid derivatives as dipeptidyl peptidase inhibitors |
| KR101333089B1 (ko) | 2006-05-22 | 2013-11-27 | 재단법인 아산사회복지재단 | 로지글리타존을 유효성분으로 함유하는 흡연-유발 만성폐쇄성 폐질환 예방 또는 치료용 약제학적 조성물 |
| JP5105297B2 (ja) * | 2006-05-25 | 2012-12-26 | 味の素株式会社 | Ｐｐａｒ活性調節剤 |
| EP1867994B1 (en) | 2006-06-13 | 2012-09-26 | Euroscreen S.A. | Ligand for G-protein coupled receptor GPR72 and uses thereof |
| CA2589393C (en) | 2006-06-13 | 2016-04-12 | Euroscreen S.A. | Ligand for g-protein coupled receptor gpr72 and uses thereof |
| JP2008044932A (ja) | 2006-07-21 | 2008-02-28 | Daiichi Sankyo Co Ltd | チアゾリジンジオン化合物を含有する組成物 |
| EP2068872A1 (en) * | 2006-09-08 | 2009-06-17 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| KR20090066289A (ko) * | 2006-09-08 | 2009-06-23 | 로드아일랜드하스피틀 | 알코올 유발성 뇌 질환의 치료, 예방 및 역행 |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| EP2066355A2 (en) * | 2006-09-19 | 2009-06-10 | Braincells, Inc. | Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis |
| US7763601B2 (en) * | 2006-11-02 | 2010-07-27 | N-Gene Research Laboratories, Inc. | Prevention and treatment of obesity |
| US8426439B2 (en) * | 2007-04-11 | 2013-04-23 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
-
2008
- 2008-04-11 US US12/101,943 patent/US8426439B2/en active Active
- 2008-04-11 MX MX2014002627A patent/MX356965B/es unknown
- 2008-04-11 ES ES08745703.2T patent/ES2438768T3/es active Active
- 2008-04-11 RU RU2009141615/15A patent/RU2492858C2/ru active
- 2008-04-11 NZ NZ580963A patent/NZ580963A/xx unknown
- 2008-04-11 CA CA2684059A patent/CA2684059C/en active Active
- 2008-04-11 EP EP08745703.2A patent/EP2141989B1/en active Active
- 2008-04-11 CN CN201510627336.5A patent/CN105250285B/zh active Active
- 2008-04-11 EP EP20189022.5A patent/EP3788877B1/en active Active
- 2008-04-11 ES ES16000588T patent/ES2830073T3/es active Active
- 2008-04-11 EP EP16000588.0A patent/EP3053440B1/en active Active
- 2008-04-11 JP JP2010503260A patent/JP5548120B2/ja active Active
- 2008-04-11 MX MX2009010854A patent/MX2009010854A/es active IP Right Grant
- 2008-04-11 CN CN201910728456.2A patent/CN110403942A/zh active Pending
- 2008-04-11 BR BRPI0810525A patent/BRPI0810525B8/pt active IP Right Grant
- 2008-04-11 ES ES13001436.8T patent/ES2586433T3/es active Active
- 2008-04-11 ES ES20189022T patent/ES2992321T3/es active Active
- 2008-04-11 KR KR1020097023578A patent/KR101622403B1/ko active Active
- 2008-04-11 WO PCT/US2008/060146 patent/WO2008128126A1/en not_active Ceased
- 2008-04-11 EP EP13001436.8A patent/EP2612553B1/en active Active
- 2008-04-11 CN CN200880019954A patent/CN101711107A/zh active Pending
- 2008-04-11 AU AU2008240158A patent/AU2008240158B2/en active Active
-
2014
- 2014-03-19 JP JP2014056079A patent/JP6010572B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024015430A5 (enExample) | ||
| RU2009141615A (ru) | Композиции и способы профилактики и лечения зависимости | |
| RU2013126476A (ru) | Лечение зависимости и расстройства побуждений с применением ингибиторов фдэ7 | |
| JP2006524261A5 (enExample) | ||
| AU2003234395B2 (en) | Abuse-resistant opioid solid dosage form | |
| JP2011126895A5 (enExample) | ||
| JP2006524249A5 (enExample) | ||
| JP2011515495A5 (enExample) | ||
| JP2009529046A5 (enExample) | ||
| JP2011519930A5 (enExample) | ||
| CA2519556A1 (en) | Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same | |
| CA2547334A1 (en) | Methods and compositions for deterring abuse of opioid containing dosage forms | |
| JP2012519675A5 (enExample) | ||
| RU2009101082A (ru) | Фармацевтические композиции | |
| CA2446738A1 (en) | Abuse-resistant opioid dosage form | |
| JP2010511683A5 (enExample) | ||
| JP2014510094A5 (enExample) | ||
| US20140141090A1 (en) | Pharmaceutical Composition Comprising Opioid Agonist And Sequestered Antagonist | |
| JP2009541320A5 (enExample) | ||
| WO2003002100A1 (en) | Tamper-proof narcotic delivery system | |
| JP2005247859A5 (enExample) | ||
| HRP20120641T1 (hr) | Oralni farmaceutski oblici doziranja otporni na neovlašteno korištenje koji sadrže opioidni analgetik | |
| SI1551372T1 (en) | SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES | |
| HRP20150835T1 (hr) | Farmaceutski oblici doziranja s kontroliranim oslobađanjem | |
| HRP20100289T1 (hr) | Proizvodi otporni na miješanje za opioidnu primjenu |